Analyst Ratings January 27, 2026

Keefe Bruyette & Woods Lifts Eagle Bancorp Price Target to $25 After Return to Profitability

Analyst keeps rating unchanged while trimming future EPS estimates amid still-elevated problem credits

By Sofia Navarro EGBN
Keefe Bruyette & Woods Lifts Eagle Bancorp Price Target to $25 After Return to Profitability
EGBN

Keefe, Bruyette & Woods increased its price objective for Eagle Bancorp (EGBN) to $25.00 from $18.00 while leaving its rating on the shares unchanged. The firm cited the bank's recent return to profitability and improvements across credit metrics, even as absolute levels of problem credits remain elevated. At the same time, KBW reduced its EPS forecasts for 2026 and 2027 on expectations of smaller reserve releases and a reduced balance sheet.

Key Points

  • Keefe, Bruyette & Woods raised its price target on Eagle Bancorp to $25.00 from $18.00, while maintaining its current rating.
  • Eagle Bancorp returned to profitability in the latest quarter, with improvements in classified and criticized assets, non-performing assets and net charge-offs.
  • KBW lowered EPS estimates to $1.20 for 2026 and $2.40 for 2027, citing expectations for less reserve release in 2026 and a smaller balance sheet in 2027; the $25 target equates to 0.7 times tangible book and 10.6 times 2027 EPS.

Keefe, Bruyette & Woods has adjusted its valuation on Eagle Bancorp (NASDAQ: EGBN), raising the price target to $25.00 from $18.00 and keeping its existing rating on the stock.

The adjustment follows Eagle Bancorp's return to profitability in the most recent quarter and noted improvements in several credit-related metrics. The research firm pointed to betterment in classified and criticized assets, non-performing assets and net charge-offs as factors supporting the higher target.

Market returns for the stock have been strong in recent periods. Data from InvestingPro shows the share price rose 16.93% over the last week and has advanced 63.66% over the past six months.

Despite those gains and the improved quarterly results, KBW highlighted that the bank's absolute level of problem credits remains high, with 10.8% categorized as classified and criticized.

The research house also adjusted its forward earnings expectations downward. KBW lowered its earnings per share estimates to $1.20 for 2026 and $2.40 for 2027, down from prior forecasts of $1.40 and $2.85, respectively. The firm explained the reductions by citing an expectation of less reserve release in 2026 and a smaller balance sheet in 2027.

Under the new price objective, the $25 target implies a valuation equal to 0.7 times tangible book value and 10.6 times the 2027 earnings per share estimate, metrics KBW used to frame the bank's restored profitability and credit improvement.

Additional company disclosures for the period show Eagle Bancorp Inc. reported fourth-quarter 2025 results that exceeded consensus expectations. The company recorded earnings per share of $0.25, compared with an anticipated loss of $0.11. Revenue for the quarter totaled $80.5 million, ahead of the expected $73.56 million.

According to the available information, there were no reported mergers or acquisitions involving Eagle Bancorp during the quarter. Likewise, there were no analyst upgrades or downgrades recorded in the period covered. These developments collectively provide insight into the bank's recent financial trajectory and the basis for KBW's revised target.

Risks

  • Absolute levels of problem credits remain elevated at 10.8% classified and criticized, which could weigh on credit-cost stability - affecting the banking sector and regional lenders.
  • KBW's lowered EPS forecasts reflect expectations for reduced reserve releases and a smaller balance sheet, introducing earnings uncertainty for upcoming years - relevant to bank earnings and investor valuation models.
  • Although recent quarterly results beat expectations, ongoing credit conditions and balance-sheet size pose risks to sustaining profitability - impacting regional banking sector sentiment.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026